Volume 14, Number 6—June 2008
Research
Validation of Syndromic Surveillance for Respiratory Pathogen Activity
Table 4
Syndrome data | RSV | Influenza A | Influenza B | S. pneumoniae (residual) | RV | PIV | Adenovirus | Enterovirus | Mycoplasma pneumoniae | Bordetella pertussis |
---|---|---|---|---|---|---|---|---|---|---|
Absenteeism | 2 | 5 | 4 | 2 | 4 | 5 | – | – | – | |
GP | –1 | 1 | 2 | –1 | 1 | 2 | −2 | – | –3 | |
Pharmacy | –1 | 0 | 2 | 0 | 2 | 5 | −2 | – | 5 | −3 |
Hospitalization | 0 | 2 | 1 | – | –2 | 3 | – | – | – | |
Laboratory submissions | –2 | 0 | 1 | –3 | – | 2 | – | 5 | | |
Mortality | −3 | 1 | 0 | – | – | – | – | – | – | |
*S. pneumoniae, Streptococcus pneumoniae; RSV, respiratory syncytial virus; RV, rhinovirus; PIV, parainfluenza virus; GP, general practice; –, pathogen not included in model.
†The lag time (in weeks) is indicated, that showed optimal fit between syndrome time-series and lagged pathogen counts included in the linear regression model; e.g., according to the model, the trend in hospitalizations precedes the influenza A laboratory counts by 2 weeks.
Page created: July 09, 2010
Page updated: July 09, 2010
Page reviewed: July 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.